Læknaneminn - 01.04.1997, Side 133

The dmg-AIDS hypothesis *
86. Stoneburner RL, Des Jarlais DC, Benezra D, Gorelkin L, Sotheran JL,
Friedman SR, Schultz S, Marmor M, Mildvan D, Maslansky R. A
larger spectrum of severe HIV-I-related disease in intravenous drug
users in New York City. Science 1988; 242: 916-919.
87. Alcabes P, Schoenbaum EE, Klein RS. Correlates of the rate of
decline of CD4+ lymphocytes among injection drug users infected
with the human immunodeficiency virus. American Journal of
Epidemiology 1993; 137: 989-1000.
88. Alcabes P, Munoz A, Vlahov D, Friedland G. Maturity of human
immunodeficiency virus infection and incubation period of acquired
immunodeficiency syndrome in injecting drug users. AIDS
Epidemiology and Pharmacology 1994; 4: 17-26.
89. Des Jarlais D, Friedman S, Marmor M, Cohen H, Mildvan D,
Yancovitz S, Mathur U, El-Sadr W, Spira TJ, Garber J. Development
of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss
in a cohort of intravenous drug users. AIDS 1987; 1: 105-111.
90. Novick DM, Ochshorn M, Ghali V, Croxson TS, Mercer WD,
Chiorazzi N, Kreek MJ. Natural killer cell activity and lymphocyte
subsets in parenteral heroin abusers and long-term methadone main-
tenance patients. The Journal of Pharmacologyt and Experimental
Therapeutics 1989; 250: 606-610.
91. Margolick JB, Munoz A, Vlahov D, Solomon L, Astemborski J, Cohn
S, Nelson KE. Changes in T-lymphocyte subsets in intravenous drug
users with HIV-1 infection. Journal of the American Medical
Association 1992; 267: 1631-1636.
92. Margolick JB, Munoz A, Vlahov D, Astemborski J, Solomon L, He X-
Y, Nelson KE, Saah AJ. Direct comparison of the relationship
between clinical outcome and change in CD4+ lymphocytes in
human immunodeficiency virus-positive homosexual men and inject-
ing drug users. Archives of Internal Medicine 1994; 154: 869-875.
93. Galli M, Lazzarin A, Saracco A, Balotta C, Castagna A, Negri C,
Ridolfo AL, Uberti-Foppa C, Corbellino M, Moroni M. Clinical and
immunological aspects of HIV infection in drug addicts. Clinical
Immunology and Immunopathology 1989; 50: S166-S176.
94. Mirken B. Everything you always wanted to know about poppers; the
“gay drug” is still here despite a ban, and so is the controversy. San
Francisco Frontiers Newsmagazine 1995; 14: 16-19, July 20.
95. St. Angelo M. Duesberg’s Questions About HIV/AIDS Merit
Answers. Windy City Times 1996: 12, April 11.
96. Lauritsen J. NIDA meeting calls for research into the poppers-
Kaposis sarcoma connection, in AIDS: Virus- or Drug Induced?, P.
H. Duesberg (eds.) Kluwer Academic Publishers, Dordrecht, 1996;
325-330.
97. Lauritsen J. The AIDS War. Asklepios (Pagan Press), New York,
1993.
98. Shilts R. And the Band Played On. St. Martins Press, New York,
1987.
99. Ineichen H. Ausgeschniiffelt? aK (Switzerland) 1996; 5: 18-19,
October November.
100. Ostrow DG. Substance abuse and HIV infection. Psychiatric
Manifestations of HIV Disease 1994; 17: 69-89.
101. Buchbinder SP, Katz MH, Hessol NA, O’MalIey PM, Holmberg
SD. Long-term HIV-1 infection without immunologic progression.
AIDS 1994; 8: 1123-1128.
102. Veugelers PJ, Page KA, Tindall B, Schechter MT, Moss AR,
Winkelstein WW, Cooper DA, Craib KJP, Charlebois E, Coutinho
RA, Van Griensven GJP. Determinants of HIV disease progression
among homsexual men registered in the tricontinental seroconvert-
er study. American Journal of Epidemiology 1994; 140: 747-758.
103. Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J,
Coulson AH, Valdiserri RO. No evidence for a role of alcohol or
other psychoactive drugs in accelerating immunodeficiency in HIV-
1-positive individuals. J Am Med Assoc 1989; 261: 3424-3429.
104. Ostrow DG, Beltran ED, Joseph JG, DiFranceisco W, Wesch J,
Chmiel JS. Recreational drugs and sexual behavior in the Chicago
MACS/CCS cohort of homosexually active men. Journal of
Substance Abuse 1993; 5: 311-325.
105. Schechter MT, Craib KJP, Montaner JSG, Le TN, O’Shaughnessy
MV, Gelmon KA. Aetiology of AIDS. Lancet 1993; 341: 1222-
1223.
106. Lau RKW, Jenkins P, Caun K, Forster SM, Weber JN, McManus TJ,
Harris JRW, Jeffries DJ, Pinching AJ. Trends in sexual behaviour in
a cohort of homosexual men: a 7 year prospective study.
International Journal of STD &C AIDS 1992; 3: 267-272.
107. Gibbons J. Drugs &: Us. Gay Times (London) 1996; 17-37,
September.
108. McManus TJ, Starrett LA, Harris JRW. Amyl Nitrite Use by
Homosexuals. Lancet 1982; i: 503.
109. LauritsenJ. NIH reconsiders nitrites’ link to AIDS. Biotechnology
1994; 12: 762-763.
110. Haverkos HW, Drotman DP. NIDA Technical Review: Nitrite
Inhalants. NIDA, Washington, D.C & CDC, Atlanta, GA 1995;
unpublished.
111. Jaffe HW, Choi K, Thomas PA, Haverkos HW, Auerbach DM,
Guinan ME, Rogers MF, Spira TJ, Darrow WW, Kramer MA,
Friedman SM, Monroe JM, Friedman-Kien AE, Laubenstein LJ,
Marmor M, Safai B, Dritz SK, Crispi SJ, Fannin SL, Orkwis JP,
Kelter A, Rushing WR, Thacker SB, Curran JW. National case-con-
trol study of Kaposi’s sarcoma and Pneumocystis carinii pneumonia
in homosexual men: Part 1, Epidemiologic results. Ann Intern Med
1983; 99: 145-151.
112. Darrow WW, Echenberg DF, Jaffe HW, O’Malley PM, Byers RH,
Getchell JP, Curran JW. Risk factors for human immunodeficiency
virus (HIV) infections in homosexual men. Am J Publ Health 1987;
77: 479-483.
113. Lifson AR, Darrow WW, Hessol NA, O’Malley PM, Barnhart JL,
Jaffe HW, Rutherford GW. Kaposi’s sarcoma in a cohort of homo-
sexual and bisexual men: epidemiology and analysis for cofactors.
Am J Epidemiol 1990; 131: 221-231.
114. Duesberg PH. Can epidemiology determine whether drugs or HIV
cause AIDS? AIDS-Forschung 1993; 12: 627-635.
115. Ellison BJ, Downey AB, Duesberg PH. HIV as a surrogate marker
for drug-use: a re-analysis of the San Francisco Men’s Health Study,
in AIDS: virus- or drug induced?, P. H. Duesberg (eds.) Kluwer
Academic Publishers, Dordrecht, The Netherlands, 1996; 97-104.
116. Schechter MT, Craib KJP, Gelmon KA, Montaner JSG, Le TN,
O’Shaughnessy MV. HIV-1 and the aetiology of AIDS. Lancet
1993; 341:658-659.
117. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA,
Becker JT, McArthur JC. Temporal trends in the incidence of HIV-
1-related neurologic diseases: Multicenter AIDS Cohort Study,
1985-1992. Neurology 1994; 44: 1892-1900.
118. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G,
Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ.
Striatal dopamine nerve terminal markers in human, chronic
metamphetamine users. Nature Medicine 1996; 2: 699-703.
119. Achard C, Bernard H, Gagneux C. Action de la morphine sur les
proprietes leucocytaires; leuco-diagnostic du morphinisme. Bulletin
et Memoires de la Societe Medicale des Hopitaux de Paris 1909; 28,
3rd Series: 958-966.
120. Pillari G, Narus J. Physical effects of heroin addiction. Am J
Nursing 1973; 73: 2105-2109.
121. Lerner WD. Cocaine abuse and acquired immunodeficiency syn-
drome: tale of two epidemics. Am J Med 1989; 87: 661-663.
122. Layon J, Idris A, Warzynski M, Sherer R, Brauner D, Patch O,
McCulley D, Orris P. Altered T-lymphocyte subsets in hospitalized
intravenous drug abusers. Arch Intern Med 1984; 144: 1376-1380.
123. Larrat PE, Zierler S. Entangled epidemics: cocaine use and HIV dis-
ease. J Psychoactive drugs 1993; 25: 207-221.
124. Pillai R, Nair BS, Watson RR. AIDS, drugs of abuse and the
immune system: a complex immunotoxicological network. Arch
Toxicol 1991; 65: 609-617.
125. Mientjes GHC, van Ameijden EJC, Weigel HM, van den Hoek
JAR, Countinho RA. Clinical symptoms associated with serocon-
version for HIV-1 among misusers of intravenous drugs: comparison
with homosexual seroconverters and infected and non-infected
intravenous drug misusers. BMJ 1993; 306: 371-373.
126. Wesson D, Smith D. Cocaine: treatment perspectives, in Cocaine
Use in America: epidemiologic and clinical perspectives, N. Kozel
and E. Adams (eds.) NIDA US Dept. HHS, Washington, DC,
1985;
127. Munoz A, Vlahov D, Solomon L, Margolick JB, Bareta JC, Cohn S,
Astemborski J, Nelson KE. Prognostic indicators for development
ofAIDS among intranvenous drug users. JAIDS 1992; 5: 694-700.
LÆKNANEMINN
131 1. tbl. 1997, 50. árg.